Semaglutide for high blood sugar after kidney transplant
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be willing to sign consent and follow the trial plan
- Be age 18 to 80
- Have high blood sugar 10 to 40 days after your kidney transplant (or had type 2 diabetes before the transplant and were on glucose-lowering medicine)
- Have enough kidney function soon after transplant (eGFR greater than 15)
- Not have type 1 diabetes, and not currently be on dialysis
- Agree to avoid certain diabetes medicines right before screening (no DPP-4 inhibitors in the last 5 days, and no GLP-1 medicines like semaglutide within 10 days)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This trial tests a medicine called an SGLT2 inhibitor (which helps lower blood sugar) in people who have had a kidney transplant and do not have diabetes. The goal is to see if it can prevent new diabetes from developing after a transplant and help protect the transplanted kidney.
This trial tests whether the medication semaglutide (often used for diabetes) can prevent the development of new diabetes after a kidney transplant. If you are in the early weeks after a transplant and have risk factors for diabetes, this study might help reduce your chances of developing diabetes later.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This Phase 2 trial tests whether combining two diabetes medicines—an SGLT2 tablet and a GLP-1 shot (semaglutide)—can improve kidney outcomes and safety in people with a kidney transplant. It may help some recipients, but it also carefully checks for infection risk, diabetes complications, and pregnancy plans.
Hear when a new Hyperglycemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.